

Ontario Public Drug Programs

Drug Submission Status

Report for March 2016

Complete Streamlined Multiple-Source

Submissions for Future Formulary Listing

The Ministry of Health and Long-Term Care has received complete submissions for the following streamlined multiple-source drug products for listing on the Ontario Drug Benefit Formulary. Subject to confirmation of Drug Identification Numbers (DIN) and prices by the manufacturers, as well as review and approval by the Executive Officer, these products may be listed as benefits in a future Formulary update. Final listing status will be communicated when the Formulary update is published on the Ministry website and via an OPDP Notice.

Manufacturer	Product	Reference Product	Generic Name	Strength	Dosage Form	DIN
Apotex Inc.	Apo-Tolterodine	Detrol	tolterodine tartrate	1mg	FC tablet	02369680
Apotex Inc.	Apo-Tolterodine	Detrol	tolterodine tartrate	2mg	FC tablet	02369699
Apotex Inc.	Apo-Capecitabine	Xeloda	capecitabine	150mg	FC tablet	02434504
Apotex Inc.	Apo-Capecitabine	Xeloda	capecitabine	500mg	FC tablet	02434512
Biomed 2002 Inc.	Bio-Donepezil	Aricept	donepezil HCl	5mg	FC tablet	02412853

Manufacturer	Product	Reference Product	Generic Name	Strength	Dosage Form	DIN
Biomed 2002 Inc.	Bio-Donepezil	Aricept	donepezil HCl	10mg	FC tablet	02412861
Sandoz Canada Inc.	Tobramycin Inhalation Solution	Tobi	tobramycin sulfate	300mg/5mL	inhalation solution	02443368
Sanis Health Inc.	Citalopram	Celexa	citalopram hydrobromide	20mg	FC tablet	02353660
Sanis Health Inc.	Citalopram	Celexa	citalopram hydrobromide	40mg	FC tablet	02353679
Vanc Pharmaceuticals Inc.	Van-Ramipril	Altace	ramipril	1.25mg	capsule	02438860
Vanc Pharmaceuticals Inc.	Van-Ramipril	Altace	ramipril	2.5mg	capsule	02438879
Vanc Pharmaceuticals Inc.	Van-Ramipril	Altace	ramipril	5mg	capsule	02438887
Vanc Pharmaceuticals Inc.	Van-Ramipril	Altace	ramipril	10mg	capsule	02438895